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rIL-2-BASED IMMUNOTHERAPY is a promising approach for pati- 
ents with advanced melanoma and renal cell carcinoma [ 11. 
IL-2 generates lymphokine-activated killing activity @AK) 
by peripheral blood lymphocytes (PBL) which acquire the 
capacity of MHC-unrestricted killing of tumour cells [2-4]. 
We have demonstrated that human tumour cell lines, resistant 
to LAK-cytotoxicity in vitro, become sensitive to cytotoxic 
lymphocytes after 24-48 h exposure to the calcium channel 
blocker verapamil [5]. Verapamil is active at concentrations 
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(lo-100 nM) which can be reached in viva [6]. Therefore, we 
designed a Phase I clinical study on rI121verapamil combi- 
nation. After committee approval, written informed consent 
was obtained Tom each patient before study entry. 
All patients enrolled in the study were given the same 
verapamil dose, while the dose of rIL-2 given by continuous 
infusion for 72 h starting day 2 was escalated in the different 
cohorts of patients (Table 1). Dose escalation was allowed if a 
minimum of 3 patients had been treated at each dose level of 
infusional rIL-2 without grade 3-4 toxicities in 2 of 3 patients. 
Dose escalation over 18 IMU/m*/day, which can be con- 
sidered a standard dose [7] and close to the maximum toler- 
ated dose (MTD) [8] of rIL-2 by continuous infusion, was not 
planned. 10 IMUim*/day rIL-2 were given by subcutaneous 
administration on days 6-10 to all patients who entered the 
study. Verapamil was administered at the dose of 0.2 mglkgih 
for 3 consecutive days by continuous infusion after a loading 
bolus dose of 0.15 mg/kg. 18 patients-8 males, 10 females, 
10 with malignant melanoma, 7 with renal cell carcinoma, 1 
with colon cancer-were enrolled in the study and completed 
the two planned courses of rIt2/verapamil. Median age was 
49 years (range 22-72). 3 additional patients were treated 
with 9 IMU/m2 rIL-2 to further explore the rIL-2 dose which 
we considered, on the basis of biological activity (see below), 
as the recommended one for Phase II trials (Table 1). 
Grade 1 elevation of BUN and creatinine occurred in 5 
patients (28%), respectively, while grade 2 increase of creatin- 
ine occurred in 1 patient (6%). Oliguria occurred in 11 
patients (6 1%) and inversion of urine electrolyte in 13 patients 
(72%). 2 patients experienced grade 2-3 hypotension which 
resulted in only temporary suspension of therapy, Grade 1 
hypotension occurred in 9 patients (50%), but did not result 
in discontinuation of drug infusion. Synus tachicardia was 
observed in 7 patients (39%), first degree atrioventricular 
(AV) heart block in 2 patients (1 l%), AV dissociation in 1 
(6%) and premature ventricular beats in 1. 1 patient had 
synus bradycardia immediately after bolus verapamil injection 
which resolved spontaneously with temporary discontinuation 
of verapamil infusion. Fever occurred in 14 (78%) patients, 
dyspnoea in 1 (6%), abdominal pain in 13 (72%), anaemia in 
10 (56%), nausea and vomiting in 4 (22%), constipation in 4 
(22%), increase of serum bilirubin in 5 (28%), diarrhoea in 
1 (6%). 
We also evaluated the immunomodulatory properties of the 
rIG2/verapamil combination by determining the number of 
circulating eosinophils and induction of cytotoxic activity 
against the human leukaemia K562 cells. Both peripheral 
blood lymphocytes cytotoxic activity and circulating eosino- 
phils were maximally increased at the rIL-2 dose of 9 
IMU/m2/day. We observed 1 complete remission in a patient 
with renal cell carcinoma, lasting 30+ months, and 2 partial 
remissions (renal cell carcinoma and melanoma), lasting 6 
and 9 months. Minor objective responses were recorded in 4 
patients (1 with melanoma and 3 with renal cell carcinoma). 
Disease progressed in 5 patients (Table 1). In conclusion, we 
demonstrated that a rIL-2 dose of 18 IMU/m* could be 
administered in combination with high-dose verapamil in 
absence of cumulative toxicity. Furthermore, this combination 
has biomodulatory properties and antitumour activity and 
deserves evaluation in Phase II clinical studies. 
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Table 1. Tumour types and responses to rIL-2lverapamil combination therapy 
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rIL-2 
(IMUlmZ/day) Tumour type Sites of disease Clinical response 
1.2 Renal cell carcinoma 
1.2 Melanoma 
1.2 Melanoma 
2.4 Colon carcinoma 
2.4 Melanoma 
2.4 Melanoma 
4.8 Melanoma 
4.8 Melanoma 
4.8 Renal cell carcinoma 
9 Melanoma 
9 Renal cell carcinoma 
9 Melanoma 
9 Renal cell carcinoma 
9 Melanoma 
9 Renal cell carcinoma 
18 Melanoma 
18 Renal cell carcinoma 
18 Renal cell carcinoma 
Liver, nodes 
Liver, bone 
Skin, nodes 
Liver, lung 
Liver, breast 
Liver, spleen, bone, lung 
Nodes 
Pleura, lung, liver, nodes 
Uterus 
Mediastinal nodes 
Adrenal gland, nodes 
Lung 
Liver 
Lung 
Nodes 
Lung, nodes 
Lung, skin, nodes 
Lung, bone 
Lung 
PD 
NC 
NC 
NC 
NC 
NC 
PD 
PD 
CR 
MR 
MR 
PR 
MR 
NC 
PD 
PD 
MR 
PR 
CR, complete remission; PR, partial remission; MR, minimal response; NC, no change; PD, 
progression of disease. 
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OVARIAN GERM cell cancer (OGCT) is a rare disease account- 
ing for less than 5% of all ovarian carcinomas. The importance 
of the disease is due to its relatively high incidence among 
children and young adults and the potential for cure by the 
use of platinum-containing chemotherapy [l]. The current 
recommendation of the Gynecologic Oncology Group 
(U.S.A.) for the treatment of advanced OGCT consists of 
cytoreductive surgery followed by three to six cycles of chemo- 
therapy with bleomycin, etoposide and cisplatin (BEP) 
resulting in a 75% cure rate for advanced stage disease [l]. 
However, treatment of platinum-refractory OGCT remains 
difficult [2]. Paclitaxel is among the few drugs that have shown 
activity in platinum-resistant ovarian and testicular germ cell 
cancer [3, 41. We report here the case of a patient with 
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